|
Hello, [Name],
|
|
My name is [name] and I’m a representative working with Avion Pharmaceuticals.
|
|
I would appreciate the opportunity to connect with you to learn more about the challenges you and your Parkinson's disease (PD) patients are facing.
|
|
|
|
PD is currently the fastest-growing neurological disorder1
|
|
|
|
|
|
60,000 new cases a year are diagnosed in the US2
|
|
|
|
|
|
Despite nearly 1 million people affected,3,4 current treatments don’t fully address the unique needs of patients with PD5
|
|
|
| |
|
Avion is excited to be entering the PD space and is committed to improving the lives of those affected by the disease.
Please let me know what time is best for you and we can set up a quick meeting.
|
|
Feel free to reach me at:
|
|
[rep email] | [rep phone number]
|
|
Sincerely,
|
|
[rep name]
|
|
[rep title]
|
|
[rep photo]
|
|
Start the conversation now
|
|
|
References: 1. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the
Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi:10.3233/JPD-181474.
2. Parkinson’s Foundation. Statistics. Accessed August 17, 2021. www.parkinson.org/Understanding-Parkinsons/Statistics 3. Yang W, Hamilton JL, Kopil C, et al. Current and
projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis.
2020;6:15. doi:10.1038/s41531-020-0117-1. 4. Tanner CM. Exploring the clinical burden of
OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 suppl):S255-S264.
doi:10.37765/ajmc.2020.88517. 5. Stoker TB, Greenland JC, eds. Parkinson’s Disease:
Pathogenesis and Clinical Aspects. Codon Publications; 2018.
|
|
|
